Skip to main content
. 2022 May 10;57(8):1250–1259. doi: 10.1038/s41409-022-01698-3

Fig. 1. FasL AM MPBCs treatment significantly reduces CD3+ cells without compromising the quantity and quality of CD34+ cells.

Fig. 1

a FasL AM MPBCs treatment process performed using the Fresenius Kabi LOVO functionally closed automated cell processing system, designed for HSCT. MPBCs graft characterization following (b–f) 100 ng/ml FasL AM treatment or (g–k) 400 ng/ml FasL AM treatment. Percentage of (b, g) CD3+ and (d, i) CD34+ cells per total CD45+ population. Percentage of annexin V positive (c, h) CD3+ and (e, j) CD34+ cells per 7AAD− population. f, k Percentage of multi potent stem and progenitor cells (CD34+CD38neg/low) per total CD34+7AAD− population. b–e: N = 16, f: N = 9, g–k: N = 3. Mean ± SEM, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; Paired T-test.